| 000 | 01046 a2200313 4500 | ||
|---|---|---|---|
| 005 | 20250513153734.0 | ||
| 264 | 0 | _c19990107 | |
| 008 | 199901s 0 0 eng d | ||
| 022 | _a0011-4162 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLebwohl, M | |
| 245 | 0 | 0 |
_aClinical efficacy and safety of tazarotene: optimizing clinical results. _h[electronic resource] |
| 260 |
_bCutis _cFeb 1998 |
||
| 300 |
_a27-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAdministration, Topical |
| 650 | 0 | 4 |
_aAdrenal Cortex Hormones _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aDermatologic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNicotinic Acids _xadministration & dosage |
| 650 | 0 | 4 | _aPilot Projects |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aPsoriasis _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tCutis _gvol. 61 _gno. 2 Suppl _gp. 27-9 |
|
| 999 |
_c9752511 _d9752511 |
||